Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 752 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patients with COVID-19 Clear all

Conditions: Covid19, Diabetes
Interventions: Not listed
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: COVID-19 Infection
Interventions: Zavegepant (BHV-3500), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: COVID
Interventions: NP-120 (Ifenprodil); Drug
Lead sponsor: Algernon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Saint Joseph, Missouri + 1 more

Conditions: Covid19
Interventions: Hyperbaric oxygen therapy; Combination Product
Lead sponsor: Peter Lindholm; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: COVID-19 Infection
Interventions: Brequinar, Placebo; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more

Conditions: Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Covid19
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas

Conditions: Post COVID-19 Syndrome
Interventions: HB-adMSCs (allogeneic), Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Covid19
Interventions: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: COVID-19
Interventions: Subjects with and without Long COVID; Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: Hydroxychloroquine, Azithromycin; Drug
Lead sponsor: LCMC Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Lung Injury, ARDS, Acute Cardiac Event, Covid19, Ultrasound, Hypoxemia, Acute Respiratory Distress Syndrome
Interventions: Point of Care Ultrasound; Diagnostic Test
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Sylmar, California • New York, New York + 1 more

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions: Not listed
Lead sponsor: BioCytics, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Huntersville, North Carolina

Conditions: COVID-19, Households, SARS CoV 2 Infection
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 374 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID
Interventions: LifeSignals Biosensor 1AX*, Standard of Care; Device · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Ischemic Heart Disease, Hopelessness, Physical Activity, Motivation, Social Support, Covid19
Interventions: Motivational social support from nurse, Motivational social support from nurse with additional support from significant other, Attention control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COVID-19
Interventions: Abatacept; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Covid-19
Interventions: CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Chula Vista, California • El Centro, California • La Mesa, California + 10 more

Conditions: SARS CoV-2 Post-Acute Sequelae
Interventions: DPA-714 PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: SARS-CoV-2 Infection
Interventions: Losartan, Placebo; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Covid19, SARS-CoV-2 Infection
Interventions: GC4419, Placebo; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Iowa City, Iowa • St Louis, Missouri

Conditions: COVID-19
Interventions: Hydroxychloroquine, Azithromycin; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 45 Years and older
Enrollment: 1,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Search by objective public record fields.

REsearching Covid-19 Outcomes in Diabetes (RECODE)

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

Aggrenox To Treat Acute Covid-19

Dysbiosis & Long COVID

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases

Use of Remote Monitoring for COVID-19 Patient

Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations

Predictors of Post-COVID-19 Clinical and Cognitive Consequences

Abatacept for Patients With COVID-19 and Respiratory Distress

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19